



EOS imaging Announces Installation in Switzerland's Largest Pediatric Hospital

Paris, November 24, 2014 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced continued adoption of the EOS imaging system in Switzerland with an installation at the University Children's Hospital Zurich (UCHZ), the country's largest university hospital for children and a leading center for pediatric and adolescent medicine in Europe. The installation at UCHZ is the Company's fifth installation in the country.

As Switzerland's largest university hospital for children, UCHZ employs 2,000 medical professionals who contribute to the welfare of more than 100,000 young patients each year. UCHZ's commitment to child welfare was honored in 2013 with the prestigious Swiss Quality Award at the National Symposium on Quality Management in Health Care in the category of patient safety.

Dr. Kellenberger, Head of Diagnostic Imaging Department at UCHZ said, "As a leading pediatric and adolescent hospital, UCHZ has the dual commitment of providing our young patients with unmatched medical care while also developing clinical research to improve patient outcomes and enhance physician training. The installation of the EOS imaging system is a natural extension of this commitment as a growing body of research has established the superiority of low-dose 2D/3D imaging."

The EOS® system provides full-body images of patients in a natural functional position in both 2D and 3D with 50% to 85% less dose than digital radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction.

Marie Meynadier, CEO of EOS imaging, said, *"The selection of EOS for 2D/3D orthopedic imaging in one of Europe's leading university hospital for children continues to affirm the strong trust and credibility that EOS imaging has cultivated among medical professionals and the research community. The low-dose stereoradiographic imaging provided by the EOS system is ideally suited for pediatric care, particularly among patients with spinal or lower limb deformities that require frequent exams."*

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

EOS imaging has been chosen to be included in the new EnterNext® PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

About EOS imaging:

EOS imaging designs, develops, and markets EOS® and associated solutions, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market in 34 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI



Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Sophie Boulila / Pierre Laurent

Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Calvin Allen

Ph: 646-536-7002

callen@theruthgroup.com